Bernie joined Nocion as Chief Medical Officer in July 2023, with over 20 years of experience in the biotechnology industry with a focus on clinical development and team building.

Since early 2019, Bernie has been consulting with innovative biotechnology companies in the Boston and New York areas. He has served as Chief Medical Officer for Lyndra Therapeutics, Nirsum Therapeutics and Nocion Therapeutics, helping them advance programs into the clinic and at times, assisting with the hiring and onboarding of full time Chief Medical Officers.

Bernie worked at Alkermes for nearly two decades and retired in 2019. During that time, he held several leadership roles in the Clinical Development, Drug Safety and Medical Affairs departments, with key roles in the development and approval of VIVITROL® (both Alcohol and Opioid Indications), ARISTADA®, ARISTADA INITIO® and LYBALVI.  He also led the clinical development of several inhaled medications including insulin, growth hormone, levodopa, salmeterol and fluticasone.

 Prior to joining Alkermes, he was Associate Professor of Pediatrics at Northwestern University and Head of the Division of Pediatric Endocrinology at Lurie Children’s Hospital, and a member of the Institutional Review Board for several years.

Bernie received a B.A. in Biophysics at the University of Pennsylvania in 1976 and an M.D. from Mount Sinai School of Medicine in 1980. Following an internship and pediatric residency at the Northwestern University, he completed additional postdoctoral training in Pediatric Endocrinology at the University of California, San Francisco. Bernie has authored numerous publications for peer reviewed journals.

• 

  Chief Medical Officer in Nocion Therapeutics

  Charging forward